Suvaxyn® MH
Aids in protection against disease caused by Mycoplasma hyopneumoniae
Safely and effectively reduces lung lesions caused by mycoplasma-induced pneumonia*
Adjuvanted with Carbopol which does not contain mineral oil, a substance believed to stimulate Porcine Circovirus Type 2 infections in pigs**
Inactivated and adjuvanted bacterin helps reduce respiratory disease severity,
as mycoplasma infections can predispose swine to Pasteurella and
Actinobacillus infections and increase their negative impact
Available in 20mL (10-dose), 100mL (50-dose), 250mL (125-dose) and 500mL (250-dose) presentations
Directions: Shake well; aseptically administer 2mL intramuscularly
Bilingual labeling
Suvaxyn® MH Information Sheet (FDP L0148D)Suvaxyn® MH Product Label
* Jensen, C.S., A.K. Ersboll, J.P. Nielsen, 2000. A Meta-analysis evaluating the effect on daily weight gain of vaccines against Mycoplasma hyopneumoniae. The 16th International Pig Veterinary Society Congress, Melbourne, Australia.
** Hoogland, B.S., T. Opriessnig, P. Halbur. 2004. Comparison of the effect of adjuvants on PCV-2 associated diseases. Proceedings of the American Association of Swine Veterinarians, p. 67-68.
